Antibody Drug Conjugates (ADC) Industry Report 2024 - Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
The global market for Antibody Drug Conjugates (ADC) was estimated at US$9.4 Billion in 2023 and is projected to reach US$23.2 Billion by 2030, growing at a CAGR of 13.8% from 2023 to 2030. Antibody Drug Conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer with high precision. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, enabling them to deliver chemotherapeutic agents directly to cancer cells while minimizing damage to healthy tissues. This targeted approach has made ADCs an increasingly attractive option in oncology, especially for cancers that have proven resistant to traditional treatments. By utilizing monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, enhancing therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various cancers, including breast cancer, lymphomas
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Non-GAAP EPS of -$0.28, revenue of $18.46M misses by $0.04M [Seeking Alpha]Seeking Alpha
- ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdatePR Newswire
- What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 11/7/24 - Beat
ADCT
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 8-K
- 11/13/24 - Form SC
- ADCT's page on the SEC website